You just read:

Rexgenero Treats First Patient in its Phase III Programme with Lead Product REX-001, a Novel Cell Therapy for the Treatment of Critical Limb Ischemia (CLI)

News provided by

Rexgenero

Jan 25, 2018, 04:00 ET